公开(公告)号：US20230000801A1

公开(公告)日：2023-01-05

申请号：US17779943

申请日：2020-11-24

申请人： CLEVEXEL PHARMA ,  INSTITUT GUSTAVE ROUSSY ,  UNIVERSITE PARIS-SACLAY

发明人： Denis BRICOUT ,  Xiuping WANG-ZHANG ,  Eric DEUTSCH ,  Céline CLEMENSON

IPC分类号： A61K31/145 ,  A61K9/19 ,  A61K47/34 ,  A61K47/26 ,  A61K9/06

摘要： A freeze-dried powder for preparing a thermogel including: from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; from 40% to 85% of one or more poloxamer; and from 0.1% to 20% of one or more carbohydrate compound.

公开(公告)号：US20230218781A1

公开(公告)日：2023-07-13

申请号：US17753893

申请日：2020-09-18

申请人： NH THERAGUIX ,  INSTITUT GUSTAVE ROUSSY ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE PARIS-SACLAY

发明人： Awatef ALLOUCH ,  Eric DEUTSCH ,  Jean-Luc PERFETTINI ,  François LUX ,  Olivier TILLEMENT

IPC分类号： A61K49/18 ,  A61K45/06

CPC分类号： A61K49/1881 ,  A61K45/06

摘要： The present disclosure relates to the field of nanomedicine, in particular for treating cancers. The present disclosure more specifically provides new methods of treating undesirable M2-polarized macrophages and/or inducing M1 macrophage polarization in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of nanoparticles containing metallic elements.

公开(公告)号：US20240153085A1

公开(公告)日：2024-05-09

申请号：US18550020

申请日：2022-03-11

申请人： INSTITUT GUSTAVE ROUSSY ,  UNIVERSITE PARIS-SACLAY ,  CENTRALESUPELEC

发明人： Marvin LEROUSSEAU ,  Eric DEUTSCH

IPC分类号： G06T7/00 ,  G16H30/40

CPC分类号： G06T7/0012 ,  G16H30/40 ,  G06T2207/20084

摘要： A method implemented by computer means for training a decision system for segmenting medical images from a training set of annotated medical images, the segments belonging to at least one class, each annotation of the medical images including quantitative information about a number of pixels of the image that belongs to each of the classes, the method using weakly-supervised algorithm based on a percentage of the pixels of the image belonging to a concerned class.

公开(公告)号：US20200239414A1

公开(公告)日：2020-07-30

申请号：US16465505

申请日：2017-11-29

申请人： CLEVEXEL PHARMA ,  INSTITUT GUSTAVE ROUSSY

发明人： Xiuping WANG-ZHANG ,  Perrine PIVETTE ,  Karine GONZALEZ ,  Eric DEUTSCH ,  Céline CLEMENSON

IPC分类号： C07C323/25 ,  A61P17/02 ,  A61K9/06 ,  A61K9/19

摘要： A process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol including the following steps: a) the reaction of a solution of amifostine with a strong acid, to obtain a solution of 2-[(3-aminopropyl)amino]ethanethiol, and b) the freeze-drying of the solution of 2-[(3-aminopropyl)amino]ethanethiol, with or without addition of excipients.

公开(公告)号：US20210003555A1

公开(公告)日：2021-01-07

申请号：US16630031

申请日：2018-07-13

申请人： Institut Gustave-Roussy

发明人： Charles FERTE ,  Elaine Johanna LIMKIN ,  Roger SUN ,  Eric DEUTSCH

IPC分类号： G01N33/50 ,  G06T7/00 ,  G16H30/40 ,  G16H50/20

摘要： The present invention proposes a radiomics-based biomarker for detecting the presence and the density of tumor infiltrating CD8 T-cells in a solid tumor without having to use any biopsy of said tumor. The invention also proposes to use this information to assess the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to prognose the survival and/or the treatment efficiency of cancer patients treated with immunotherapy such as anti-PD-1/PD-L1 monotherapy.

公开(公告)号：US20200181714A1

公开(公告)日：2020-06-11

申请号：US16333409

申请日：2017-09-19

申请人： Institut Gustave-Roussy

发明人： Jean-Luc PERFETTINI ,  Eric DEUTSCH ,  Awatef ALLOUCH

IPC分类号： C12Q1/6886 ,  C07K14/80

摘要： Although tumor-associated macrophages have been extensively studied in the control of response to radiotherapy, the molecular mechanisms involved in the ionizing radiation-mediated activation of macrophages remain elusive. Here the present inventors show that ionizing radiation induces the expression of interferon-regulatory factor 5 (IRF5) promoting thus macrophage activation toward a pro-inflammatory phenotype. They reveal that the activation of the Ataxia telangiectasia mutated (ATM) kinase is required for ionizing radiation-elicited macrophage activation, but also for macrophage reprogramming after treatments with γ-interferon, lipopolysaccharide or chemotherapeutic agent (such as cis-platin), underscoring the fact that the kinase ATM plays a central role during macrophage phenotypic switching toward a proinflammatory phenotype. They further demonstrate that NADPH oxidase 2 (NOX2)-dependent ROS production is upstream to ATM activation and is essential during this process. They also report that hypoxic conditions and the inhibition of any component of this signaling pathway (NOX2, ROS and ATM) impairs pro-inflammatory activation of macrophages and predicts a poor tumor response to preoperative radiotherapy in locally advanced rectal cancer. Altogether, these results identify a novel signaling pathway involved in macrophage activation that may enhance effectiveness of radiotherapy through the re-programming of tumor infiltrating macrophages.

公开(公告)号：US20210128730A1

公开(公告)日：2021-05-06

申请号：US16628611

申请日：2018-07-04

申请人： NH THERAGUIX ,  Universite Claude Bernard Lyon 1 ,  Centre National de La Recherche Scientifique - CNRS - ,  INSERM (Institut National de la Sante et de la Recherche Médicale) ,  Institut Gustave Roussy

发明人： François LUX ,  Olivier TILLEMENT ,  Jean-Luc PERFETTINI ,  Eric DEUTSCH ,  Frédéric LAW ,  Awatef ALLOUCH

IPC分类号： A61K41/00 ,  A61P35/00 ,  A61K9/51 ,  A61N5/10 ,  A61K33/24

摘要： The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.

公开(公告)号：US20190201480A1

公开(公告)日：2019-07-04

申请号：US16243654

申请日：2019-01-09

申请人： INSTITUT CURIE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSTITUT GUSTAVE ROUSSY ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM) ,  UNIVERSITE RENE DESCARTES - PARIS V

发明人： Eric DEUTSCH ,  Johannes LUDGER ,  Michele MONDINI ,  Mevyn NIZARD ,  Jean-Luc PERFETTINI ,  Eric TARTOUR ,  Thi TRAN

IPC分类号： A61K38/16 ,  A61K47/64 ,  A61K41/00 ,  A61N5/10

CPC分类号： A61K38/164 ,  A61K41/0038 ,  A61K47/6415 ,  A61K47/646 ,  A61N5/10 ,  A61N2005/1098

摘要： Disclosed is a composition for use in the prevention or treatment of a subject suffering from a cancer in combination with radiotherapy, wherein the composition includes a conjugate, eventually associated with pharmaceutically acceptable carrier, the conjugate including i) the Shiga Toxin B subunit (STxB), a fragment or a derivative thereof; and ii) at least one epitope associated with the cancer.

公开(公告)号：US20220257709A1

公开(公告)日：2022-08-18

申请号：US17626360

申请日：2020-07-17

申请人： Institut Gustave-Roussy

发明人： Jean-Luc PERFETTINI ,  Awatef ALLOUCH ,  Eric DEUTSCH

IPC分类号： A61K38/17 ,  C12N5/0786 ,  C12N15/86 ,  C12N15/90 ,  A61K35/15 ,  A61P35/02 ,  A61K45/06

摘要： Identification of effective targets alleviating the programmed cell removal (PrCR) of tumor cells by macrophages is of very high interest. The present inventors have identified that the cyclin-dependent kinase inhibitor p21 protein is a strong regulator of the macrophage-mediated PrCR. Also, they showed that the adoptive transfer of p21 overexpressing monocytes induces macrophage PrCR and transition from an anti-inflammatory to a pro-inflammatory phenotype in vivo, delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia.

公开(公告)号：US20210060029A1

公开(公告)日：2021-03-04

申请号：US16963338

申请日：2019-01-23

申请人： Institut Gustave-Roussy

发明人： Jean Luc PERFETTINI ,  Eric DEUTSCH ,  Catherine BRENNER ,  Jean-Christophe CINTRAT ,  Frederic TARAN

IPC分类号： A61K31/5377 ,  A61K9/00 ,  A61P35/00

摘要： The present invention is drawn to the use of Minaprine dihydrochloride and analogs thereof, for reducing tumor growth when administered to a patient suffering from cancer.